Reconstitution of humoral immunity and decreased risk of infections in patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors
- 6 June 2020
- journal article
- research article
- Published by Taylor & Francis Ltd in Leukemia & Lymphoma
- Vol. 61 (10), 2375-2382
- https://doi.org/10.1080/10428194.2020.1772477
Abstract
Immune dysregulation in chronic lymphocytic leukemia (CLL) contributes to a high rate of infections and morbidity. The Bruton tyrosine kinase (BTK) inhibitors ibrutinib and acalabrutinib mark major breakthroughs in the treatment of CLL, however many patients require long-term therapy with these agents. Despite receiving effective therapy for CLL, patients on BTK inhibitors remain immunocompromised and at risk of infectious complications. We previously reported that treatment of CLL with ibrutinib leads to partial reconstitution of humoral immunity and fewer infections during the first two years of therapy. It is currently unclear whether the positive effects of ibrutinib on the immune system are sustained during long-term therapy. Acalabrutinib is a newer, more selective BTK inhibitor than ibrutinib; however a detailed evaluation of the immunologic impact of acalabrutinib therapy is lacking. Herein, utilizing two independent trials, we assessed the immunological effects and infectious risk of ibrutinib and acalabrutinib treatment in patients with CLL.This publication has 34 references indexed in Scilit:
- Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinibBlood, 2015
- Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trialThe Lancet Oncology, 2014
- Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytesBlood, 2013
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic LeukemiaThe New England Journal of Medicine, 2013
- Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approachesBest Practice & Research Clinical Haematology, 2010
- Adaptive linear step-up procedures that control the false discovery rateBiometrika, 2006
- Standards for child and adolescent immunization practices. National Vaccine Advisory Committee.2003
- Disease activity and pretreatment, rather than hypogammaglobulinaemia, are major risk factors for infectious complications in patients with chronic lymphocytic leukaemiaBritish Journal of Haematology, 2003
- Infections in Chronic Lymphocytic Leukemia: Risk Factors, and Impact on Survival, and TreatmentLeukemia & Lymphoma, 1994
- Serum immunoglobulins in B-chronic lymphocytic leukemia.Natural history and prognostic significanceCancer, 1988